Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and ro

U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong resu

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”

What happened Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Legal Officer and Corporate Secretary He

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Comp

Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s stock price gapped up prior to trading o

JP Morgan analyst Hardik Parikh initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Ove

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains

U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a

Spyre Therapeutics (NASDAQ: SYRE - Get Free Report) and Gain Therapeutics (NASDAQ: GANX - Get Free R

California State Teachers Retirement System grew its stake in shares of Spyre Therapeutics, Inc. (NA

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ: SYRE) d

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcr

SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.

Wedbush analyst David Nierengarten reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Outperform

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains

SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.00

SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p

WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Com

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinic

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock?

Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lower

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward bro

Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock is trading lower on Wednesday after the company shared

Spyre Therapeutics shared Phase 2 SKYWAY trial data for SPY072 in rheumatoid arthritis. The therapy

Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform a

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market

US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted ea

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the

JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares

Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market s

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or m

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in

Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts

Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downg

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the

To test the hypothesis of the SPY772 program, the company also announced the initiation of SKYLIGHT,

Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and ra

Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises

Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform a

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.36) per share which beat the analy

Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers incl

Mizuho analyst Joseph Catanzaro maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and

U.S. stock futures mixed, Nasdaq 100 falls 200 pts. Rivian (RIVN) drops after public offering announ

U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates

Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 mil

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth

Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY